

No data available
No data available
No data available
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Revenue | 63.12 | 53.87 | 39.62 | 44.98 |
| Total Expenses | 56.64 | 49.38 | 37.07 | 41.19 |
| Profit Before Tax | 6.48 | 4.49 | 2.55 | 3.80 |
| Profit After Tax | 4.95 | 3.63 | 1.84 | 3.35 |
| Operating Profit After Depreciation | 8.46 | 6.60 | 3.10 | 4.31 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Fixed Assets | 40.90 | 43.48 | 42.50 | 17.23 |
| Total Non Current Assets | 42.06 | 44.58 | 44.16 | 22.41 |
| Total Current Assets | 49.19 | 29.56 | 14.56 | 14.43 |
| Total Assets | 91.25 | 74.14 | 58.72 | 36.84 |
| Total Shareholder's Fund | 55.62 | 25.29 | 18.20 | 16.38 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Cash From Operating Activities | 1.42 | 1.52 | 1.96 | 0.49 |
| Net Cash Used In Investing Activities | 0.66 | -3.15 | -22.68 | -5.78 |
| Net Cash Used In Financing Activities | 5.07 | 3.09 | 16.43 | 5.20 |
No data available
No data available
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
No data available
On 13 November 2025
11 Nov 2025, 09:49 am
On 27 September 2025
06 Sep 2025, 09:43 am
On 28 May 2025
24 May 2025, 08:09 pm
Shares of Onyx Biotec were trading at Rs 56.75 on the NSE, a discount of 6.97% compared with the issue price of Rs 61.
22 Nov 2024, 05:38 pm

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.